Active, Not Recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
NCT06786520
- Conditions
- Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
- Locations
-
- GSK Investigational Site Mobile, Alabama, United States
- GSK Investigational Site Coral Gables, Florida, United States
- GSK Investigational Site Oak Brook, Illinois, United States